T cells are the immune system’s frontline fighters. When they detect danger, they rapidly multiply and transform into ...

Cabaletta announced promising results of its lead T-cell therapy candidate targeting autoimmune diseases. Eagles owner ...

The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our ...

Cullinan Therapeutics has announced a licensing agreement with Genrix Bio for global rights to velinotamig, a clinical-stage ...

Genrix’s velinotamig complements Cullinan’s own pipeline, according to William Blair, which added that the deal will put ...

HIV/AIDS remains a major public health threat worldwide, with an estimated 39.9 million people living with the disease at the ...

Researchers found that immune T cells reside in healthy brains, signaling between the gut and brain, a previously unknown ...

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...

Immune cells play fundamental roles in the development, progression, and resolution of both chronic inflammatory diseases and various cancer types. In ...

A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...